Towards a pathway definition of Parkinson’s disease: a complex disorder with links to cancer, diabetes and inflammation

We have previously established a first whole genome transcriptomic profile of sporadic Parkinson’s disease (PD). After extensive brain tissue-based validation combined with cycles of iterative data analysis and by focusing on the most comparable cases of the cohort, we have refined our analysis and established a list of 892 highly dysregulated priority genes that are considered to form the core of the diseased Parkinsonian metabolic network. The substantia nigra pathways, now under scrutiny, contain more than 100 genes whose association with PD is known from the literature. Of those, more than 40 genes belong to the highly significantly dysregulated group identified in our dataset. Apart from the complete list of 892 priority genes, we present pathways revealing PD ‘hub’ as well as ‘peripheral’ network genes. The latter include Lewy body components or interact with known PD genes. Biological associations of PD with cancer, diabetes and inflammation are discussed and interactions of the priority genes with several drugs are provided. Our study illustrates the value of rigorous clinico-pathological correlation when analysing high-throughput data to make optimal use of the histopathological phenome, or morphonome which currently serves as the key diagnostic reference for most human diseases. The need for systematic human tissue banking, following the highest possible professional and ethical standard to enable sustainability, becomes evident.

[1]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[2]  M. Boranić,et al.  A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. , 1979, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[3]  R Sandyk,et al.  The relationship between diabetes mellitus and Parkinson's disease. , 1993, The International journal of neuroscience.

[4]  M. Muenter,et al.  Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma , 1995, Movement disorders : official journal of the Movement Disorder Society.

[5]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[6]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[7]  L. Moran,et al.  Mechanisms of Cell Death in Neurodegenerative Diseases: Fashion, Fiction, and Facts , 2002, Brain pathology.

[8]  S. Ackerman,et al.  Oxidative stress, cell cycle, and neurodegeneration. , 2003, The Journal of clinical investigation.

[9]  W. Willett,et al.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.

[10]  M. Ristow,et al.  Neurodegenerative disorders associated with diabetes mellitus , 2004, Journal of Molecular Medicine.

[11]  Sergei Maslov,et al.  Automatic Pathway Building in Biological Association Networks , 2006 .

[12]  L. Moran,et al.  Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease , 2006, Neurogenetics.

[13]  T. Dawson,et al.  To die or grow: Parkinson's disease and cancer , 2005, Trends in Neurosciences.

[14]  F. Middleton,et al.  Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[15]  E. Gelmann,et al.  The ubiquitin-proteasome pathway and its role in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Wenhua Liu,et al.  Selective Vulnerability of Dopaminergic Neurons to Microtubule Depolymerization* , 2005, Journal of Biological Chemistry.

[17]  R. Jensen,et al.  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. , 2005, Archives of neurology.

[18]  P. Hevezi,et al.  Gene expression analyses reveal molecular relationships among 20 regions of the human CNS , 2006, Neurogenetics.

[19]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[20]  L. Moran,et al.  Correction: Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition , 2006, Journal of Neuroinflammation.

[21]  L. Moran,et al.  Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra , 2007, Acta Neuropathologica.

[22]  T. Mak,et al.  DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 , 2006, Proceedings of the National Academy of Sciences.

[23]  Yongjin Li,et al.  Discovering disease-genes by topological features in human protein-protein interaction network , 2006, Bioinform..

[24]  A. Sidhu,et al.  An Inflammatory Pathomechanism for Parkinsons Disease , 2006 .

[25]  W. Kukull,et al.  Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[26]  S. Rosso,et al.  Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature , 2006, Melanoma research.

[27]  T. Joh,et al.  Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease , 2006, Experimental & Molecular Medicine.

[28]  H. Checkoway,et al.  Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. , 2006, Parkinsonism & related disorders.

[29]  M. Graeber,et al.  Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration , 2006, Acta Neuropathologica.

[30]  Zhen Yan,et al.  Neurotrophic Factors Stabilize Microtubules and Protect against Rotenone Toxicity on Dopaminergic Neurons* , 2006, Journal of Biological Chemistry.

[31]  C. Shults.  Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Moran,et al.  Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease , 2006, Neurogenetics.

[33]  A. Sidhu,et al.  An inflammatory pathomechanism for Parkinson's disease? , 2006, Current medicinal chemistry.

[34]  Ramón Díaz-Uriarte,et al.  IDconverter and IDClight: Conversion and annotation of gene and protein IDs , 2007, BMC Bioinformatics.

[35]  T. Mak,et al.  Tumours and tremors: how PTEN regulation underlies both , 2006, British Journal of Cancer.

[36]  T. Kaysser-Kranich,et al.  Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease , 2006, Neurobiology of Disease.

[37]  P S Whitton,et al.  Inflammation as a causative factor in the aetiology of Parkinson's disease , 2007, British journal of pharmacology.

[38]  X. Zhuang,et al.  Absence of Ret Signaling in Mice Causes Progressive and Late Degeneration of the Nigrostriatal System , 2007, PLoS biology.

[39]  A. Hofman,et al.  Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease , 2007, Neuroepidemiology.

[40]  A. Barabasi,et al.  Network medicine--from obesity to the "diseasome". , 2007, The New England journal of medicine.

[41]  A. Mills,et al.  p53: at the crossroad between cancer and ageing , 2007, The Journal of pathology.

[42]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[43]  Manuel B. Graeber,et al.  Neuronal pentraxin II is highly upregulated in Parkinson’s disease and a novel component of Lewy bodies , 2007, Acta Neuropathologica.

[44]  M. Frosch,et al.  Effects of gender on nigral gene expression and parkinson disease , 2007, Neurobiology of Disease.

[45]  D. Bennett,et al.  Diabetes and Parkinsonian Signs in Older Persons , 2007, Alzheimer Disease and Associated Disorders.

[46]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[47]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[48]  M. Farrer,et al.  ARE PARKINSON DISEASE PATIENTS PROTECTED FROM SOME BUT NOT ALL CANCERS? , 2008, Neurology.